Fig. 2: CVnCoV and CV2CoV prevent replication of SARS-CoV-2 variants BavPat1 and B.1.351 in K18-hACE2 mice. | Nature Communications

Fig. 2: CVnCoV and CV2CoV prevent replication of SARS-CoV-2 variants BavPat1 and B.1.351 in K18-hACE2 mice.

From: CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2

Fig. 2: CVnCoV and CV2CoV prevent replication of SARS-CoV-2 variants BavPat1 and B.1.351 in K18-hACE2 mice.The alternative text for this image may have been generated using AI.

RT-qPCR for genomic RNA of SARS-CoV-2 was performed with a oral swab samples at day 4 or from organ samples of b the upper respiratory tract, c, d the lower respiratory tract (caudal lung = circle; cranial lung = squares), and e, f the brain at day 10 or at the humane endpoint. Mice that were vaccinated with 8 µg CVnCoV (orange) or different concentrations of CV2CoV (0.5 µg (light green), 2 µg (green) or 8 µg (dark green)), received 106 FI-Virus (blue) or NaCl (black) (sham) on days 0 and 28 followed by i.n. challenge with 105.9 TCID50 of SARS-CoV-2 variant BavPat1 or 105.5 TCID50 B1.351. Each dot represents one individual mouse. Each sample was tested once, and assays were repeated at least once. p Values were determined by nonparametric one-way ANOVA and Dunn’s multiple comparisons test. Scatter plots are labeled with median (height of the bar) and interquartile range. Differences were considered significant at p < 0.05, with exact p values displayed in the figure. Source data are provided as a Source data file.

Back to article page